Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

Moderna’s third quarter was shaped by sharply lower demand for COVID-19 vaccines, yet the company delivered results above ...

Q3 2025 Earnings Call Transcript November 6, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-0.51282, ...

A new delivery particle developed at MIT could make mRNA vaccines more effective and potentially lower the cost per vaccine ...

The team used the AMG1541 LNP to deliver an mRNA influenza vaccine in mice. They compared this vaccine’s effectiveness to a flu vaccine made with the lipid SM-102, which is FDA-approved and was used ...

Moderna's mRNA-1273 vaccine helped prevent medically attended COVID-19 and related hospitalizations across multiple respiratory seasons among adults.

A presentation by scientists on a work group for the Centers for Disease Control and Prevention’s vaccine advisory panel ...

A new lipid nanoparticle could make mRNA vaccines more effective and potentially lower the cost per dose. New research suggests an mRNA influenza vaccine delivered with the new particle could generate ...

With continued investment in mRNA research, Donald Trump could turn the stalemate against cancer into a decisive breakthrough ...

New research found that mRNA vaccines for COVID-19 could enhance cancer treatments and help patients live longer.

Learn more about whether Moderna, Inc. or Viridian Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.